Active-ingredient Dossier
Trastuzumab
Active-ingredient Dossier for Trastuzumab (monoclonal antibody). Australian brands, products, PBS listings, PBAC outcomes — compiled by arcimedes.
- Brand: HERCEPTIN
- Brand: OGIVRI
- Brand: TRASTUCIP
- Brand: TUZUCIP
- Brand: HERZUMA
- Brand: PHESGO SC
- Therapeutic area: Oncology
What is
Trastuzumab Trastuzumab is a monoclonal antibody active ingredient.
Australian brands containing
Trastuzumab The following brands containing trastuzumab are registered on the ARTG: — HERCEPTIN — OGIVRI — TRASTUCIP — TUZUCIP — KANJINTI — HERZUMA — TRAZIMERA — ONTRUZANT — PHESGO SC
Therapeutic areas
Trastuzumab is registered in oncology, with 9 brands containing the ingredient.
Sponsor landscape
Trastuzumab is marketed by seven sponsors: Roche Products, Cipla, Celltrion Healthcare, Amgen, Maxx Pharma, and Samsung Bioepis AU.
PBS and regulatory activity
Two brands containing trastuzumab have PBS-listed items, with a latest PBS schedule date of 1 May 2026. In the 2021–22 financial year, government expenditure on trastuzumab was approximately $70.6 million across 62,071 prescriptions. The latest PBAC outcome was recorded on 1 March 2022, with six brands having PBAC outcomes on record. The latest AusPAR was published on 7 July 2022, with three brands having AusPARs on record.